Phase 3
Completed N=339
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
Source: ClinicalTrials.gov NCT02135692 ↗Enrolled (actual)
339
Serious AEs
24.8%
Results posted
May 2018
Primary outcomePrimary: Annualized Rate of On-treatment Exacerbations Per Year — 0.93 Exacerbations per year
◆ Published Evidence
Highly cited
165citations · ~24 / year
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Summary
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma. This study will enroll a subset of subjects from Study MEA115661 who have demonstrated clear benefit from therapy and who without continuation of mepolizumab therapy are individuals at greatest risk of serious deterioration of their health status. In order to target individuals at greatest risk for serious deterioration of their health status, only subjects from the MEA115661 study with a history of life-threatening or seriously debilitating asthma, will be allowed to participate. Subjects meeting all of the eligibility criteria for the study will be offered the opportunity to consent for this study of up to 128 weeks in length (including the Follow-Up Visit). This study will give opportunity to extend the collection of clinical data for long-term use and further assess the sustainability of efficacy in a population likely to experience significant loss of asthma control and the need for higher doses of systemic steroids if returned to SOC only.
Linked Publications
-
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Annualized Rate of On-treatment Exacerbations Per Year |
0.93 | — |
| PRIMARY Number of Participants With Any On-treatment Adverse Event (AE) or On-treatment Serious AE (SAE) |
315; 84 | — |
| SECONDARY Mean Change From Baseline in Asthma Control Questionnaire (ACQ)-5 On-treatment Score |
-0.16; -0.15; -0.21; -0.17; -0.18; -0.08 | — |
| SECONDARY Mean Change From Baseline in On-treatment Clinic Pre-bronchodilator FEV1 |
67; 27; 30; 47; 34; 14 | — |
| SECONDARY Number of Participants Withdrawn From the Study Due to Lack of Efficacy and Adverse Events |
2; 3 | — |
| SECONDARY Number of Participants Hospitalized Due to Adverse Events Including Asthma Exacerbations |
78 | — |
| SECONDARY Number of Participants With AEs Including Both Systemic (Allergic and Non-allergic) and Local Site Reactions |
2; 14 | — |
| SECONDARY Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTcB) and QT Interval Corrected by Fridericia's Method (QTcF) Values for 12-lead Electrocardiogram (ECG) |
0.1; -0.9; -2.9; -0.6; 0.5; 1.8 | — |
| SECONDARY Number of Participants With Maximum Change From Baseline in QTcB and QTcF Interval for ECG Assessed at Any Time Post Baseline |
0; 1; 70; 196; 35; 3 | — |
| SECONDARY Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure |
1.8; 0.6; 1.5; 2.0; 1.2; 1.8 | — |
| SECONDARY Change From Baseline in Pulse Rate |
2.1; 2.3; 2.6; 2.1; 2.7; 1.2 | — |
| SECONDARY Number of Participants With Positive Anti-mepolizumab Binding Antibodies (ADA) and Neutralizing Antibodies (NAb) |
6; 329; 0; 6 | — |
| SECONDARY Number of Participants With Potential Clinical Importance Values for Change From Baseline Relative to the Reference Range for Clinical Chemistry Parameters at Any Time Post-Baseline |
1; 334; 1; 0; 337; 0 | — |
| SECONDARY Number of Participants With Potential Clinical Importance Values for Change From Baseline Relative to the Reference Range for Hematology Parameters at Any Time Post-Baseline |
1; 335; 0; 1; 335; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent.
- Male or Eligible Female Subjects: To be eligible for the study, females of child-bearing potential must commit to consistent and correct use of an acceptable method of birth control and for 4 months after the last study drug administration. A urine pregnancy test is required of all females of childbearing potential at the initial Baseline Visit (Visit 1).
- French Subjects Only: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
- MEA115661 Participation: Subjects must have completed Visit 14 of MEA115661.
- Current Anti-Asthma Therapy: The subject's asthma has been treated with an ICS controller medication for the last 8 months with fluticasone propionate (FP) >=500 mcg/day (or equivalent).
- Disease Severity: Subjects must be assessed as having life-threatening /serious debilitating asthma in order to enroll, as defined by the following: Subjects enrolled in MEA115588 must meet one of the following criteria: a) Subject has a history of at least one intubation during their lifetime; b) >=3 asthma exacerbations in the 12 months prior to screening for MEA115588; c) >=1 or more hospitalization for asthma exacerbation in the 12 months prior to screening for MEA115588. Subjects enrolled in MEA115575 must meet one of the following criteria: d) Subject has a history of at least one intubation during their lifetime; e) Their optimized dose at randomization in MEA115575 was >=10mg of prednisone; f) >=1 or more hospitalization for asthma exacerbation in the 12 months prior to screening for MEA115575.
- Clinical Benefit: Subjects must have experienced documented clinical benefit to enroll. Subjects must meet the following criteria demonstrating clinical benefit: Subjects enrolled in MEA115588 who received mepolizumab must meet all of the following criteria: a) Subject must have had a reduction in their exacerbation frequency by >=50% during MEA115588. The baseline for comparison is the total number of exacerbations reported in the 12 months prior to screening for MEA115588. b) The investigator response on the "Clinician-Rated Response to Therapy" questionnaire at Visit 10 was either: mildly improved, moderately improved or significantly improved. Subjects enrolled in MEA115588 who received placebo must meet all of the following criteria: c) Subject must have had a reduction in their exacerbation frequency by >=50% during the first 8 months of MEA115661. The baseline for comparison is the total number of exacerbations reported in the 12 months prior to screening for MEA115588; d) The investigator confirms that the subject demonstrated improvement during MEA115661. Subjects enrolled in MEA115575 who received mepolizumab must meet all of the following criteria: e) Subject must have reduced their oral corticosteroid dose by >=50% during MEA115575. The baseline for comparison is the subject's optimized oral corticosteroid (OCS) dose at randomization in MEA115575; f) The investigator response on the "Clinician-Rated Response to Therapy" questionnaire at Visit 9 was either: mildly improved, moderately improved or significantly improved. Subjects enrolled in MEA115575 who received placebo must meet all of the following criteria: g) Subject must have reduced their oral corticosteroid dose at randomization by >=50% in the first 6 months of MEA115661. The baseline for comparison is the subject's optimized OCS dose at randomization in MEA115575; h) The investigator confirms that the subject demonstrated improvement during MEA115661.
Exclusion Criteria
- Health Status: Clinically significant change in health status during MEA115661 which in the opinion of the investigator would make the subject unsuitable for participation in this long-term study.
- Pregnancy: Subjects who are pregnant or breastf
Data sourced from ClinicalTrials.gov (NCT02135692) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.